Botulism

Botulism is a rare but severe, toxin-mediated neuroparalytic illness caused by botulinum neurotoxin (BoNT), produced almost always by Clostridium botulinum — a gram-positive, anaerobic, spore-forming bacterium — and only rarely by toxin-producing strains of Clostridium baratii or Clostridium butyricum. Botulinum neurotoxins are the most potent biological toxins known.^[1]

The toxin binds irreversibly to presynaptic cholinergic nerve terminals — at the neuromuscular junction and at autonomic synapses — where it cleaves the SNARE proteins required for acetylcholine-containing vesicles to fuse with the nerve terminal membrane. The result is a block of acetylcholine release that only resolves as new nerve terminals regenerate, producing a symmetric, descending flaccid paralysis that begins with the cranial nerves and autonomic findings, and characteristically spares sensation entirely.^[1][2] Regardless of how the toxin was acquired, the clinical picture it produces is essentially the same.^[2]

There are five recognized routes of exposure: foodborne (ingestion of preformed toxin), wound (spores germinate and produce toxin locally in an anaerobic wound), infant (ingested spores germinate and produce toxin in an immature infant gut), adult intestinal colonization (the same intestinal mechanism as infant botulism, occurring rarely in adults with disrupted gut flora or anatomy), and iatrogenic (unintended systemic spread of therapeutically or cosmetically injected botulinum toxin).^[2]

The classic pattern

Early symptoms reflect bilateral cranial nerve involvement: blurred or double vision (diplopia), drooping eyelids (ptosis), slurred speech (dysarthria), a hoarse or weak voice (dysphonia), and difficulty swallowing (dysphagia) — sometimes summarized as the "4 Ds": diplopia, dysarthria, dysphonia, and dysphagia.^[3] Dry mouth is frequently an early complaint, reflecting the toxin's effect on autonomic cholinergic synapses as well as the neuromuscular junction.^[2]

From the cranial nerves, weakness characteristically descends — to the neck and upper extremities, then the trunk and lower extremities, and in severe cases to the muscles of respiration, causing respiratory failure. Autonomic findings often accompany the motor findings: dilated or sluggishly reactive pupils, ileus, constipation, and urinary retention.^[1][2]

Bilateral total ophthalmoplegia with ptosis, and a fixed, dilated pupil, in a 14-year-old with wound botulism following a compound arm fracture — the descending cranial-nerve pattern that should trigger suspicion regardless of the patient's age. (Herbert L. Fred, MD & Hendrik A. van Dijk, CC BY 2.0, Wikimedia Commons)

Two negative findings that matter as much as the positive ones

Two features are genuinely central to recognizing botulism, precisely because their presence should make the diagnosis less likely: patients are classically afebrile (fever occurs only if a complicating infection is also present), and fully alert and oriented with no sensory findings whatsoever — paradoxically mentally intact despite advancing paralysis.^[2][1] This combination — afebrile, mentally intact, symmetric descending paralysis without sensory loss — is the single most useful bedside clue distinguishing botulism from its principal mimics (see Assessment & Diagnosis).^[1]

Presentation by subtype

• Home-canned, home-preserved, or fermented foods not processed to eliminate C. botulinum spores or prevent toxin formation — home-canned vegetables, cured meats and ham, and smoked or fermented fish are the most frequently implicated categories.^[6][7]
• Traditionally prepared, fermented marine-mammal and fish products (seal, whale, walrus, fermented fish eggs) made without refrigeration — a well-documented, though substantially reduced, source of foodborne (largely toxin type E) botulism in northern and Indigenous communities in Canada; see Special Populations.^[7][2]
• Injection drug use, particularly subcutaneous or intramuscular injection ("skin-popping") of black tar heroin — the dominant risk factor for wound botulism in North America.^[2][8]
• Any traumatic or contaminated wound, including a compound fracture, even without drug use.^[2]
• Infants younger than 12 months given honey in any form — the only food definitively linked to infant botulism, though it accounts for only a small proportion of cases.^[9][2]
• Infants exposed to disturbed soil or household dust — a more common, though far less modifiable, source of the spores that cause infant botulism than honey.^[2]
• Cosmetic or therapeutic botulinum toxin injection, especially with an unregulated, unlicensed, or counterfeit product, or at a dose or injection site outside approved use.^[4][5]
• Immunocompromised status, recent antimicrobial therapy, inflammatory bowel disease, or prior gastrointestinal surgery altering gut flora or anatomy — risk factors specific to adult intestinal colonization botulism.^[2]

Botulism is a clinical diagnosis — treatment must never wait for laboratory confirmation

Diagnosis rests on history and a thorough, serial neurologic examination. Confirmatory testing typically takes days to complete and can be falsely negative even in genuine disease, so the diagnostic and treatment decision has to be made on clinical grounds.^[2][1][3] Current guidance specifically recommends considering botulism whenever myasthenia gravis or Guillain-Barré syndrome is being considered, and in any patient with unexplained, symmetric cranial nerve palsies with or without other muscle weakness.^[1]

Differentiating botulism from its principal mimics

Botulism is frequently misdiagnosed, most often as Guillain-Barré syndrome (or its Miller Fisher variant), myasthenia gravis, or a primary CNS event such as stroke.^[1] The pattern below is the most useful bedside discriminator.

^[1]

Electrodiagnostic testing

Electromyography, repetitive nerve stimulation, and nerve conduction studies can support the diagnosis when the picture is unclear. Classical findings include an incremental response to repetitive nerve stimulation at 30-50 Hz, fibrillation, decreased recruitment of motor units, decreased motor unit potential duration, and decreased motor-evoked amplitude on nerve conduction studies with otherwise normal findings — though testing can be entirely normal early in the illness, and is not needed to justify starting antitoxin when the clinical picture is already convincing.^[1]

Laboratory confirmation

Confirmation relies on detecting botulinum toxin (by mouse bioassay, the diagnostic gold standard, or by newer immunoassay/cell-based methods) in serum, stool, gastric aspirate, wound tissue, or suspect food, or on isolating C. botulinum itself from stool, gastric aspirate, or a wound. Whenever feasible, collect serum for toxin testing before antitoxin is given, since antitoxin will neutralize circulating toxin and can produce a false-negative result — but this should never delay treatment itself.^[2][1]

^[2][10]

Routine bloodwork (CBC) and, where a lumbar puncture is performed, CSF studies are typically normal in botulism — a genuinely useful negative finding, since an elevated CSF protein points toward Guillain-Barré syndrome instead.^[1] Because manipulating botulinum toxin and viable C. botulinum carries its own laboratory biosafety requirements, testing is performed only at a designated public health reference laboratory — notify local public health immediately once botulism is suspected so that specimen collection and shipment, and the parallel process of arranging antitoxin, can proceed together rather than sequentially.^[2]

• Halt further progression of paralysis with antitoxin as early as possible — antitoxin cannot reverse paralysis that has already occurred, so speed matters more than for almost any other therapy in this platform's library.
• Protect the airway and support ventilation proactively, before overt respiratory failure develops.
• Achieve source control for wound botulism through debridement and drainage.
• Prevent further toxin absorption or production where relevant (removing unabsorbed foodborne toxin from the gut, treating a local wound infection).
• Provide meticulous supportive and nutritional care through what can be a weeks-to-months recovery, since this — more than any single drug — is what has driven the case-fatality rate down over the past century.
• Notify public health immediately and support the outbreak investigation for foodborne cases, to identify and protect other people who may share the same exposure.
• Educate the patient, family, or caregiver on the specific prevention point relevant to their case — honey avoidance, safe home-canning practice, or harm-reduction guidance — to prevent a recurrence.

Which antitoxin, and how to access it in Canada

Two distinct antitoxin products exist, and neither is stocked for routine use or approved for sale in Canada — both require an emergency application through Health Canada's Special Access Programme (SAP), coordinated through the local Medical Health Officer and the provincial public health laboratory/CDC.^[2]

Wound botulism — antibiotics have a role here, but only for source control

Wound botulism in addition to antitoxin, debride the wound and establish drainage, and treat any secondary/local wound infection with an antibiotic — antibiotics do not neutralize circulating toxin, only the local bacterial infection.^[2] Avoid aminoglycosides they independently potentiate neuromuscular blockade and can worsen the paralysis itself.^[1][2] Use caution with clindamycin and penicillins current guidance flags both as carrying a theoretical risk in botulism and recommends weighing risks and benefits individually against any comorbid indication, rather than reaching for either by default.^[1]

Do not use antibiotics to treat the toxin itself

Foodborne, infant, and adult intestinal colonization botulism antibiotics are not recommended for these forms specifically because there is no infected wound to treat — lysis of C. botulinum by an antibiotic could theoretically increase the amount of toxin released and available for absorption.^[2]

No other proven pharmacotherapy

No other agent has been shown effective for botulism, including activated charcoal, polyethylene glycol, cholinergic agonists, or plasmapheresis; use magnesium, calcium, monoamine oxidase inhibitors, and neuromuscular blocking agents cautiously if at all, since each can plausibly worsen neuromuscular transmission in a patient already close to respiratory failure.^[1] Antitoxin is not useful as postexposure prophylaxis for an asymptomatic person with a shared exposure — monitor closely instead, and treat promptly with antitoxin at the very first sign of illness.^[2][1]

• Hospitalize every suspected case, with ICU-level monitoring and serial vital capacity measurement — the goal is a low threshold for elective intubation and mechanical ventilation, arranged calmly and in advance, rather than emergency intubation after overt respiratory failure develops.^[1]
• Wound botulism: debride the wound and establish drainage in addition to antitoxin and antibiotics — this is core therapy, not an adjunct.^[2]
• Provide nutritional support (nasogastric or parenteral, as needed) proactively, given the prolonged dysphagia and ileus that can accompany the illness.
• For a patient with a confirmed or strongly suspected foodborne exposure, and within an appropriate window, unabsorbed toxin remaining in the gastrointestinal tract may be purged with cathartics, gastric lavage, or a high enema, under close medical supervision — these measures are not used in infant botulism.^[2]
• Arrange physical, occupational, and respiratory therapy proactively — recovery is genuinely protracted, often weeks to months, as new nerve terminals sprout to bypass the blocked synapses, and rehabilitation needs should be anticipated rather than addressed only once weaning begins.^[1]
• Standard precautions are sufficient — no isolation is required, and no case of person-to-person transmission of botulism has been documented, including in healthcare settings.^[1]
• Infants (and adult intestinal colonization patients) can shed C. botulinum organism and toxin in the stool for weeks to months after the acute illness resolves — reinforce hand hygiene for caregivers and careful handling and disposal of diapers at discharge.^[1]
• Meticulous supportive and nutritional care is, alongside antitoxin, the other half of why the case-fatality rate has fallen from roughly 70% in the early 1900s to about 5-10% today — it is not merely an adjunct to drug therapy.^[1][2]

Infants younger than 12 months

Infant botulism is the most commonly reported form of botulism in North America, most often affecting infants between 6 weeks and 6 months of age.^[2] The single most important, actionable prevention message do not give honey — raw, pasteurized, or cooked/baked into any food, or added to a soother — to an infant younger than 12 months. Honey is the only food definitively linked to infant botulism in Canada, though it accounts for only a minority of cases; there were 38 reported cases of infant botulism in Canada between 1979 and 2010.^[9] Disturbed soil or household dust is a more common, though far less modifiable, source of the spores that cause infant botulism.^[2] BabyBIG (see Choose Initial Treatment) is the preferred antitoxin for confirmed type A or B infant botulism; BAT is used for other or unconfirmed toxin types.^[2]

An infant with confirmed botulism — unable to open his eyes or move, with a barely audible cry, while fully awake and not sedated. This is the "floppy baby" pattern of progressive hypotonia and cranial nerve involvement described in Recognize the Condition. (Momofbear, CC BY-SA 3.0, Wikimedia Commons)

People who inject drugs

Maintain a high index of suspicion for wound botulism in any person who injects drugs — particularly black tar heroin injected subcutaneously or intramuscularly ("skin-popping") — presenting with unexplained cranial nerve findings, even if the injection site looks unremarkable and even if the patient does not volunteer a substance-use history.^[2][8] A 2017-2018 outbreak among people who used black tar heroin in San Diego County illustrates how these outbreaks cluster and how easily individual cases can be missed early.^[8] This encounter is also a genuine opportunity for harm-reduction counseling and referral, alongside the emergency botulism workup itself.

Indigenous and northern communities

Traditionally prepared, fermented marine-mammal and fish products (seal, whale, walrus, fermented fish eggs) made without refrigeration remain a recognized source of foodborne botulism — predominantly toxin type E — in northern and Indigenous communities in Canada, though the share of national cases arising from Indigenous communities fell from 85% (1990-2005) to 46% (2006-2021) following targeted risk-communication and food-safety education, particularly around promptly chilling butchered meat below 4°C.^[7] The right response to this risk is honest, collaborative risk-reduction messaging about preparation and storage — not discouraging traditional food practices; in British Columbia, the First Nations Health Authority is specifically invited to participate in case management whenever a suspected case is Indigenous.^[2]

Cosmetic and therapeutic botulinum toxin recipients

Iatrogenic botulism is rare but genuinely under-recognized, and has been reported even at doses used for routine cosmetic indications through unintended systemic spread of the toxin.^[5] Recent outbreaks — including a cluster linked to unregulated botulinum toxin used for obesity treatment in Türkiye in 2023 — underscore that unlicensed product and off-label, excessive dosing are the dominant drivers.^[4] Counsel patients considering cosmetic botulinum toxin injection to use only a licensed practitioner and an approved product (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, or letibotulinumtoxinA — see Drug Tables); if iatrogenic botulism is suspected, confirm exactly which product, dose, and injection site the patient received as part of the emergency workup.

Pregnancy

Pregnancy is not a contraindication to botulinum antitoxin — treat as aggressively and as promptly as in a non-pregnant patient, given the maternal respiratory risk of untreated disease, and involve obstetrics or maternal-fetal medicine early.^[1]

Immunocompromised adults and altered gastrointestinal anatomy or flora

These patients are the population at risk for adult intestinal colonization botulism. Relapsing or fluctuating symptoms during otherwise adequate antitoxin treatment can occur because of ongoing intraluminal toxin production, and should prompt reconsideration of repeat antitoxin dosing and gastroenterology involvement for the underlying gastrointestinal abnormality, rather than being assumed to reflect treatment failure.^[2]

Renal and hepatic impairment

No antitoxin dose adjustment is required for renal or hepatic impairment. Adjust supportive-care medications used during the ICU stay (sedation, analgesia, and any antibiotic given for wound botulism source control) according to their own usual organ-impairment principles.

Monitor respiratory status closely and continuously through the acute illness — serial vital capacity measurement, with a proactive, low threshold for intubation and mechanical ventilation, is the standard rather than waiting for a dramatic clinical deterioration.^[1]

• Anticipate a genuinely protracted recovery — paralysis can persist for weeks to months as new nerve terminals regenerate and reinnervate the neuromuscular junction — and arrange physical, occupational, and speech-language therapy (for dysphagia) proactively rather than only once ventilator weaning begins.^[1][2]
• Infants and adult intestinal colonization patients can continue to shed C. botulinum organism and toxin in the stool for weeks to months after the acute illness resolves; reinforce caregiver hand hygiene and careful diaper handling/disposal at discharge, even though no person-to-person transmission has ever been documented.^[1]
• Complete the required Health Canada SAP follow-up reporting (Form C) after any BabyBIG use, and ensure the case is formally reported to public health within the applicable provincial timeline if this was not already completed at presentation.^[2]
• For foodborne cases, expect ongoing public health follow-up of household members and other people who may have shared the same food exposure, and continued food-source investigation — support this rather than treating it as complete once the index patient is stabilized.^[2]
• At outpatient follow-up after discharge, reassess for residual weakness or fatigue, and screen for the psychological impact of a prolonged ICU stay and mechanical ventilation, which is easy to overlook once the acute paralysis has resolved.

1. Weakness or respiratory status still progressing after antitoxin has been given: this is expected in the short term — antitoxin only prevents further toxin from binding, it does not reverse an existing block — so reassess and escalate airway/ventilatory support proactively rather than interpreting ongoing progression as a treatment failure requiring diagnostic reconsideration on its own.^[1]
2. No improvement at all, together with a discordant feature — fever, true sensory loss, an ascending rather than descending pattern, or an elevated CSF protein: reconsider the diagnosis and pursue the Guillain-Barré syndrome or myasthenia gravis pathway instead, without abandoning botulism entirely if the picture later shifts back.^[1]
3. Wound botulism with persistent or recurrent toxemia despite antitoxin and antibiotics: reassess for an incompletely debrided source and consider repeat surgical exploration and debridement.^[2]
4. Adult intestinal colonization botulism with relapsing symptoms during otherwise adequate antitoxin treatment: this reflects ongoing intraluminal toxin production rather than a failed initial dose — involve gastroenterology for the underlying gut abnormality and consider repeat antitoxin dosing.^[2]
5. Any diagnostic uncertainty, or a barrier to accessing antitoxin: escalate directly and immediately to the treating hospital's on-call physician, the local Medical Health Officer, and the provincial public health laboratory/CDC — do not wait for a scheduled follow-up call, and do not delay further while troubleshooting the request alone.^[2]

• Waiting for mouse bioassay or other laboratory confirmation — which can take days and can still be falsely negative — before starting antitoxin or escalating to emergency care.^[2][1]
• Missing wound botulism in a person who injects drugs because the injection site looks unremarkable, or because the patient does not volunteer a substance-use history.^[2][8]
• Giving any honey-containing food or product to an infant younger than 12 months.^[9]
• Using an aminoglycoside for the wound infection in wound botulism — it independently potentiates neuromuscular blockade and can worsen the paralysis itself.^[1]
• Reaching for antibiotics to try to treat foodborne, infant, or adult intestinal colonization botulism itself, rather than reserving them strictly for a documented secondary/local infection in wound botulism.^[2]
• Treating the presence of fever or true sensory symptoms as consistent with botulism — either finding should prompt reconsidering the diagnosis rather than being explained away.^[2][1]
• Delaying public health notification until the diagnosis feels fully confirmed, rather than notifying in parallel with treatment from the moment botulism is clinically suspected.^[2]
• Treating a single case of foodborne botulism as an isolated event rather than a potential outbreak requiring prompt investigation of anyone who may share the same food exposure.^[2]
• Assuming pregnancy is a contraindication to antitoxin — it is not.^[1]
• Assuming BabyBIG is appropriate for every infant botulism case — it is specific to toxin types A and B; other or unconfirmed types need BAT instead.^[2]
• Assuming a normal early electrodiagnostic study excludes botulism — testing can be entirely normal early in the illness.^[1]

How to use this table: antitoxin doses require patient-specific confirmation through the access pathway described in Choose Initial Treatment; antibiotic doses require confirmation against local protocol, wound severity, and culture results. Select any drug name to open its complete Pharmasist Drug Database page.

Botulism Antitoxins

Neither product is stocked for routine use or approved for sale in Canada — both require an emergency Health Canada Special Access Programme application, coordinated through the local Medical Health Officer. See Choose Initial Treatment for the full access process.

Wound Botulism — Antibiotics for the Local/Secondary Infection Only

These treat the wound infection itself, not the circulating toxin — debridement and drainage remain equally essential alongside antitoxin. Select and dose according to wound severity, culture results, and local protocol.

Antibiotics to Avoid or Use With Caution in Any Form of Botulism

Listed because they are commonly reached for empirically in a patient with a wound or a presumed infection — in botulism specifically, each carries an added risk beyond its usual adverse-effect profile.

Cosmetic/Therapeutic Botulinum Toxin Products — Relevant to Iatrogenic Botulism, Not a Treatment for It

Included so the pharmacist can confirm exactly which product, dose, and injection site a patient received when iatrogenic botulism is suspected — none of these treats botulism itself.